Similarly, T2D therapies appear to be effective in returning the expression of LEP and IL-6 by IPFP-ASCs to levels found in Non-T2D, suggesting that earlier T2D intervention may be required, especially in patients who also exhibit OA symptoms. This evidence concerns the gene IL6 and type 2 diabetes mellitus.